How patient understanding shaped a better, integrated approach to orphan drug wrap-around services

Rare disease patient adherence currently averages at only 58-65 percent. These results are unacceptable, and have many orphan drug manufacturers considering how to refine their market access, pricing and distribution strategies. Equally important, new insights from clinical care experts and patient advocacy organizations call attention to the unknown and unmet needs of the patient journey.

In the new white paper, Precision Medicine meets Precision Patient Support, Dohmen Life Science Services showcases a more comprehensive approach to patient understanding and how it shapes a fully integrated exclusive distribution model, featuring wrap-around patient services to drive better outcomes. 

Download your copy today to learn more.

Expert insights include:
Nicole Boice, Global Genes CEO: “A better understanding, ideally, would facilitate a true partnership among patient communities and the industry. It would inform the development of support programs that would have a meaningful impact on patients’ and families’ lives. Any time a company truly understands the patient experience and journey, it is a win-win for all involved.”

Linda Newberry-Ferguson, DLSS Senior Vice President of Clinical Navigation. “You’ve got to see the patient as an individual, not a category or community. Patients with the same disease on the same therapy will often have different needs and reasons for nonadherence.”